EIB-funding will accelerate development of the Histolog® Scanner and reinforce commercialisation efforts across Europe and United States LUXEMBOURG & BRUSSELS &EIB-funding will accelerate development of the Histolog® Scanner and reinforce commercialisation efforts across Europe and United States LUXEMBOURG & BRUSSELS &

EIB Provides €20 Million in Financing to SamanTree Medical for Real-Time Microscopy for Surgical Procedures

2026/01/27 14:15
3 min read

EIB-funding will accelerate development of the Histolog® Scanner and reinforce commercialisation efforts across Europe and United States

LUXEMBOURG & BRUSSELS & LIEGE, Belgium–(BUSINESS WIRE)–#EIB—SamanTree Medical, a European leader in surgical imaging innovation, has secured €20 million in financing from the European Investment Bank (EIB). The operation is backed by InvestEU, the EU’s flagship program to mobilize over €372 billion in additional investment from 2021 to 2027.

The financing supports the development of an advanced confocal microscopy scanner for rapid imaging of the internal microstructure of tissue samples during surgical procedures. Furthermore, the financing will support SamanTree Medical’s research, development and innovative activities, including continued development and advancement of its Histolog® Scanner

The EIB financing is provided through the Bank’s Venture Debt Instrument and is designed to support highly innovative companies undertaking research-intensive development activities.

“The support of the European Investment Bank represents an important milestone for SamanTree,” said Olivier Delporte, CEO of SamanTree Medical. “This financing allows us to accelerate development of the Histolog Scanner and expand our commercial presence across Europe and the United States. The rigorous due diligence process undertaken by the EIB reflects the importance of our innovative technology, our development plan and our long-term vision for advancing real-time, high-resolution imaging for excised tissue.”

Our investment in SamanTree Medical reflects the EIB’s long-standing commitment to advancing medical innovation across Europe,” said EIB Director Alessandro Izzo. “By supporting med‑tech companies through venture debt, a tool that helps entrepreneurs accelerate growth and bring cutting-edge technologies to patients sooner, we make sure that key medical tech companies can grow and thrive in Europe. Supporting innovators like SamanTree Medical is central to our mission of driving positive impact for patients and healthcare systems.”

The advanced technique of the Histolog Scanner enables it to capture nearly 30,000 images simultaneously, rather than one at a time, producing high-resolution, histology-like images in approximately one minute without damaging the specimen. This allows surgeons and pathologists to image tissue within minutes and determine whether abnormal cellular microstructures remain at the surgical site, while patients remain on the operating table. Used in more than 6,000 patients to date, physicians using the Histolog Scanner have demonstrated compelling results across multiple tissue types. In breast-conserving surgery, the SHIELD study showed that when physicians used the Histolog images for assessment, reoperation rates were lowered from 30% to 10%, a 67% reduction.

Research has also shown that Histolog is similar1 when compared to intraoperative frozen-section analysis (the gold standard) for prostatectomies, while offering substantial time savings. Using Histolog for imaging and interpretation takes approximately 5-20 minutes, compared with 45-60 minutes for frozen section analysis.2 Using the Histolog images, physicians have also demonstrated a sensitivity ranging from 73% – 91% and a specificity ranging from 91% to 100%, when compared to conventional pathology.1,2,3 Additionally, studies have shown that intraoperative assessment allows surgeons to opt for more nerve-sparing surgeries, significantly reducing erectile dysfunction, a common side effect of a radical prostatectomy.4

Background

The European Investment Bank (EIB) is the long-term lending institution of the European Union, owned by its Member States.

Headquartered in Liège, Belgium, SamanTree Medical is a privately held company dedicated to improving oncologic surgery through innovative imaging solutions.

1 https://pubmed.ncbi.nlm.nih.gov/39403832/
2 https://pubmed.ncbi.nlm.nih.gov/36440864/
3IP8-FLUORESCE: A Prospective Paired Cohort Study Evaluating the Diagnostic Accuracy of Fluorescence Confocal Microscopy for Real-time Assessment of Surgical Margins in Radical Prostatectomy – PubMed
4 https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00091-9/fulltext

Contacts

Media contact
SamanTree: Amy Cook | +1 925 222 5094 | amy.cook@samantree.com

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Cashing In On University Patents Means Giving Up On Our Innovation Future

Cashing In On University Patents Means Giving Up On Our Innovation Future

The post Cashing In On University Patents Means Giving Up On Our Innovation Future appeared on BitcoinEthereumNews.com. “It’s a raid on American innovation that would deliver pennies to the Treasury while kneecapping the very engine of our economic and medical progress,” writes Pipes. Getty Images Washington is addicted to taxing success. Now, Commerce Secretary Howard Lutnick is floating a plan to skim half the patent earnings from inventions developed at universities with federal funding. It’s being sold as a way to shore up programs like Social Security. In reality, it’s a raid on American innovation that would deliver pennies to the Treasury while kneecapping the very engine of our economic and medical progress. Yes, taxpayer dollars support early-stage research. But the real payoff comes later—in the jobs created, cures discovered, and industries launched when universities and private industry turn those discoveries into real products. By comparison, the sums at stake in patent licensing are trivial. Universities collectively earn only about $3.6 billion annually in patent income—less than the federal government spends on Social Security in a single day. Even confiscating half would barely register against a $6 trillion federal budget. And yet the damage from such a policy would be anything but trivial. The true return on taxpayer investment isn’t in licensing checks sent to Washington, but in the downstream economic activity that federally supported research unleashes. Thanks to the bipartisan Bayh-Dole Act of 1980, universities and private industry have powerful incentives to translate early-stage discoveries into real-world products. Before Bayh-Dole, the government hoarded patents from federally funded research, and fewer than 5% were ever licensed. Once universities could own and license their own inventions, innovation exploded. The result has been one of the best returns on investment in government history. Since 1996, university research has added nearly $2 trillion to U.S. industrial output, supported 6.5 million jobs, and launched more than 19,000 startups. Those companies pay…
Share
BitcoinEthereumNews2025/09/18 03:26
VIRTUAL Bearish Analysis Feb 10

VIRTUAL Bearish Analysis Feb 10

The post VIRTUAL Bearish Analysis Feb 10 appeared on BitcoinEthereumNews.com. VIRTUAL is approaching a critical support test at the 0.55$ level, with RSI at 33
Share
BitcoinEthereumNews2026/02/10 15:15
XRPL Developer Says 100% Taking Profits on XRP at $10, $27

XRPL Developer Says 100% Taking Profits on XRP at $10, $27

An XRPL developer has stirred discussion around profit-taking levels well above today’s price, prompting mixed reactions from XRP holders who favor a never-sell
Share
Coinstats2026/02/10 15:11